Marshall Wace
ALPN

Marshall Wace’s Alpine Immune Sciences Inc ALPN Stock Holding History

Marshall Wace’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-221,118
Closed -$4.21M – 2902
2023
Q4 		$4.21M Buy
+221,118
New +$3.07M 0.01% 967
2022
Q4 		– Sell
-45,077
Closed -$323K – 3562
2022
Q3 		$323K Buy
45,077
+9,147
+25% +$75.4K ﹤0.01% 2921
2022
Q2 		$305K Buy
+35,930
New +$310K ﹤0.01% 3025

Other funds holding ALPN

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Marshall Wace's ALPN Position: Q1 2024 in Review

Marshall Wace sold out of Alpine Immune Sciences Inc (ALPN) in Q1 2024, closing a stake of 221,118 shares — an estimated $4.21M sold.

Marshall Wace first reported a position in ALPN in Q2 2022 and held it in 3 quarters. The position peaked at $4.21M in Q4 2023. 180 funds tracked by Wall St. Rank hold ALPN as of Q1 2024.

  • Marshall Wace reported no remaining Alpine Immune Sciences Inc position as of Q1 2024 after selling out during the quarter.
  • Marshall Wace sold 221,118 Alpine Immune Sciences Inc shares in Q1 2024, an estimated $4.21M.
  • Marshall Wace first reported a position in Alpine Immune Sciences Inc in Q2 2022 and held it in 3 quarters.
  • Marshall Wace's Alpine Immune Sciences Inc position peaked at $4.21M in Q4 2023.
  • 180 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q1 2024.

Based on Marshall Wace's 13F filing for Q1 2024, filed 15 May 2024.